Phillippe Puech
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Phillippe Puech has a total of 188 co-authors. Here are the top co-authors by number of shared publications:
- Arnauld Villers
Department of Urology, Lille University Hospital, 59000 Lille, France
16 shared publications - Nacim Betrouni
Univ. Lille, INSERM, UMR1172 -Lille Neuroscience & Cognition, F-59000 Lille, France
7 shared publications A. Ouzzane
Service d'urologie, hôpital Huriez, CHRU de Lille, 1, place de Verdun, 59037 Lille, France
5 shared publicationsLaurent Lemaitre
Department of Radiology, Lille University Hospital, Lille University, 59000 Lille, France
5 shared publications- Laurent Lemaître
Service d'imagerie néphro-urologique et ORL, université Lille, hôpital Claude-Huriez, CHRU de Lille, 1, rue Michel-Polonovski, 59037 Lille cedex, France; Inserm U703, université Lille Nord de France, CHRU de Lille, 59120 Loos, France
5 shared publications Adil Ouzzane
3 shared publications
Latest Publications
- Open Access
- 10 November 2025
- Published by Springer Nature in Pediatric Radiology
- Vol. 56 (2) , 415-423
Diagnostic utility of magnetic resonance urography in pediatric ureteropelvic junction obstruction: evaluating changes in anteroposterior diameter of the renal pelvis following furosemide administration
Background: Magnetic resonance urography (MRU) with diuretic injection is increasingly used to evaluate pediatric ureteropelvic junction obstruction, providing anatomical and functional information without ionizing radiation. Objective: To analyze the increase in anteroposterior diameter of the renal pelvis following furosemide injection during MRU to determine a diagnostic cutoff. To assess whether this increase supports etiological diagnosis and whether magnetic resonance imaging (MRI) reliably detects crossing vessels. Materials and methods: We retrospectively included all children who underwent surgery for ureteropelvic junction obstruction at our institution between January 2010 and January 2023 and had preoperative MRU. For each patient, the increase in renal pelvis diameter after furosemide injection during MRU was measured on the obstructed and contralateral healthy sides. Measurements were compared to determine a pathological cutoff. The change in renal pelvis diameter was also compared according to etiology (intrinsic vs. extrinsic). The association between crossing vessels identified on MRI and intraoperative findings was also assessed. Results: Seventy patients (median age 9) were included. The increase in renal pelvis diameter was significantly greater on the obstructed side compared to the contralateral side ( P < 0.001). The optimal cutoff for predicting obstruction was 6 mm (sensitivity 68.6%, specificity 87.1%). No significant difference was found in the change in renal pelvis diameter according to etiology ( P = 0.86). The association between crossing vessels identified on MRI and during surgery was significant ( P < 0.001). Conclusion: An increase greater than 6 mm in renal pelvis diameter after furosemide injection during MRU could represent an additional diagnostic criterion for pediatric ureteropelvic junction obstruction. Graphical
- 10 November 2025
- Published by Springer Nature in Pediatric Radiology
- Vol. 56 (2) , 415-423
Open AccessDiagnostic utility of magnetic resonance urography in pediatric ureteropelvic junction obstruction: evaluating changes in anteroposterior diameter of the renal pelvis following furosemide administration
Background: Magnetic resonance urography (MRU) with diuretic injection is increasingly used to evaluate pediatric ureteropelvic junction obstruction, providing anatomical and functional information without ionizing radiation. Objective: To analyze the increase in anteroposterior diameter of the renal pelvis following furosemide injection during MRU to determine a diagnostic cutoff. To assess whether this increase supports etiological diagnosis and whether magnetic resonance imaging (MRI) reliably detects crossing vessels. Materials and methods: We retrospectively included all children who underwent surgery for ureteropelvic junction obstruction at our institution between January 2010 and January 2023 and had preoperative MRU. For each patient, the increase in renal pelvis diameter after furosemide injection during MRU was measured on the obstructed and contralateral healthy sides. Measurements were compared to determine a pathological cutoff. The change in renal pelvis diameter was also compared according to etiology (intrinsic vs. extrinsic). The association between crossing vessels identified on MRI and intraoperative findings was also assessed. Results: Seventy patients (median age 9) were included. The increase in renal pelvis diameter was significantly greater on the obstructed side compared to the contralateral side ( P < 0.001). The optimal cutoff for predicting obstruction was 6 mm (sensitivity 68.6%, specificity 87.1%). No significant difference was found in the change in renal pelvis diameter according to etiology ( P = 0.86). The association between crossing vessels identified on MRI and during surgery was significant ( P < 0.001). Conclusion: An increase greater than 6 mm in renal pelvis diameter after furosemide injection during MRU could represent an additional diagnostic criterion for pediatric ureteropelvic junction obstruction. Graphical
- Open Access
PI-RADS v2 is a Strong Prognostic Marker for Adverse Outcomes in Prostate Cancer
Importance: Magnetic Resonance Imaging (MRI) coupled with Prostate Imaging-Reporting and Data System (PI-RADS) provides a standardized scoring system for assessing the clinical significance of prostate cancer (PCa). The association between PI-RADS scores and key clinical end-points remains underexplored due to limited follow-up data. Objective: To evaluate the association of PI-RADS with prostate cancer-specific mortality (PCSM), overall survival (OS), metastasis-free survival (MFS), and biochemical recurrence (BCR) across three cohorts. Design, Setting, Participants: A retrospective registry cohort, Helsinki University Hospital (HUS) for men with clinical suspicion of PCa, included 4,674 men who underwent diagnostic MRI during the PI-RADS version-2 era (2015-2019, median follow-up [mFU] 5.0 years). Validation cohorts were: Tampere University Hospital (n=1,474, 2016-2021, mFU 2.2 years) and Lille University Hospital (N=301, 2016-2024, mFU 6.2 years). Exposures: Diagnostic MRI imaging was scored using PI-RADS v2. Main outcomes and measures: Primary outcomes were PCSM, OS, MFS, and BCR. Secondary measures included clinical confounders, such as age, Grade Group (GG), and Charlson’s Comorbidity Index (CCI). Results: 84 of 4,674 HUS-cohort patients (1.7%) died of PCa, with 79 patients (94%) presenting with PI-RADS score 5. Multivariable Cox regression adjusted for clinical confounders found PI-RADS score 5 was significantly associated with PCSM (Hazard Ratio (HR) 18.4, 95% CI [6.62-51.1], p<0.001), along with biopsy GG 5 (HR 5.45 [1.82-16.3], p=0.002), CCI (HR 1.53 [1.42-1.7], p<0.001), and log2-PSA (HR 1.28 [1.11-1.5], p<0.001). Kaplan-Meier curves demonstrated negligible PCSM after negative MRI (nMRI; PI-RADS score 0-2) (log-rank p<0.001). PI-RADS score 5 was associated with OS in the Helsinki and Tampere cohorts (p<0.001) and MFS and BCR in the Lille cohort (p<0.001). Conclusion and relevance: PI-RADS score 5 is strongly associated with an increased risk of PCSM and other clinically relevant outcomes. A non-suspicious MRI associates with a negligible risk of adverse outcomes. These findings support the use of MRI for risk stratification in PCa.
Open AccessPI-RADS v2 is a Strong Prognostic Marker for Adverse Outcomes in Prostate Cancer
Importance: Magnetic Resonance Imaging (MRI) coupled with Prostate Imaging-Reporting and Data System (PI-RADS) provides a standardized scoring system for assessing the clinical significance of prostate cancer (PCa). The association between PI-RADS scores and key clinical end-points remains underexplored due to limited follow-up data. Objective: To evaluate the association of PI-RADS with prostate cancer-specific mortality (PCSM), overall survival (OS), metastasis-free survival (MFS), and biochemical recurrence (BCR) across three cohorts. Design, Setting, Participants: A retrospective registry cohort, Helsinki University Hospital (HUS) for men with clinical suspicion of PCa, included 4,674 men who underwent diagnostic MRI during the PI-RADS version-2 era (2015-2019, median follow-up [mFU] 5.0 years). Validation cohorts were: Tampere University Hospital (n=1,474, 2016-2021, mFU 2.2 years) and Lille University Hospital (N=301, 2016-2024, mFU 6.2 years). Exposures: Diagnostic MRI imaging was scored using PI-RADS v2. Main outcomes and measures: Primary outcomes were PCSM, OS, MFS, and BCR. Secondary measures included clinical confounders, such as age, Grade Group (GG), and Charlson’s Comorbidity Index (CCI). Results: 84 of 4,674 HUS-cohort patients (1.7%) died of PCa, with 79 patients (94%) presenting with PI-RADS score 5. Multivariable Cox regression adjusted for clinical confounders found PI-RADS score 5 was significantly associated with PCSM (Hazard Ratio (HR) 18.4, 95% CI [6.62-51.1], p<0.001), along with biopsy GG 5 (HR 5.45 [1.82-16.3], p=0.002), CCI (HR 1.53 [1.42-1.7], p<0.001), and log2-PSA (HR 1.28 [1.11-1.5], p<0.001). Kaplan-Meier curves demonstrated negligible PCSM after negative MRI (nMRI; PI-RADS score 0-2) (log-rank p<0.001). PI-RADS score 5 was associated with OS in the Helsinki and Tampere cohorts (p<0.001) and MFS and BCR in the Lille cohort (p<0.001). Conclusion and relevance: PI-RADS score 5 is strongly associated with an increased risk of PCSM and other clinically relevant outcomes. A non-suspicious MRI associates with a negligible risk of adverse outcomes. These findings support the use of MRI for risk stratification in PCa.
- Open Access
- 25 August 2023
- Published by Elsevier in European Journal of Radiology
- Vol. 167, 111027
MA-QC: Free online software for prostate MR quality control and PI-QUAL assessment
- 25 August 2023
- Published by Elsevier in European Journal of Radiology
- Vol. 167, 111027
Open AccessMA-QC: Free online software for prostate MR quality control and PI-QUAL assessment
- 6 May 2023
- Published by Springer Nature in European Radiology
- Vol. 33 (10) , 7212-7214
How should we prepare a generation of radiologists for MRI-based prostate cancer screening?
- 6 May 2023
- Published by Springer Nature in European Radiology
- Vol. 33 (10) , 7212-7214
How should we prepare a generation of radiologists for MRI-based prostate cancer screening?
- Open Access
International Multi-Site Initiative to Develop an MRI-Inclusive Nomogram for Side-Specific Prediction of Extraprostatic Extension of Prostate Cancer
Background: To develop an international, multi-site nomogram for side-specific prediction of extraprostatic extension (EPE) of prostate cancer based on clinical, biopsy, and magnetic resonance imaging- (MRI) derived data. Methods: Ten institutions from the USA and Europe contributed clinical and side-specific biopsy and MRI variables of consecutive patients who underwent prostatectomy. A logistic regression model was used to develop a nomogram for predicting side-specific EPE on prostatectomy specimens. The performance of the statistical model was evaluated by bootstrap resampling and cross validation and compared with the performance of benchmark models that do not incorporate MRI findings. Results: Data from 840 patients were analyzed; pathologic EPE was found in 320/840 (31.8%). The nomogram model included patient age, prostate-specific antigen density, side-specific biopsy data (i.e., Gleason grade group, percent positive cores, tumor extent), and side-specific MRI features (i.e., presence of a PI-RADSv2 4 or 5 lesion, level of suspicion for EPE, length of capsular contact). The area under the receiver operating characteristic curve of the new, MRI-inclusive model (0.828, 95% confidence limits: 0.805, 0.852) was significantly higher than that of any of the benchmark models (p < 0.001 for all). Conclusions: In an international, multi-site study, we developed an MRI-inclusive nomogram for the side-specific prediction of EPE of prostate cancer that demonstrated significantly greater accuracy than clinical benchmark models.
Open AccessInternational Multi-Site Initiative to Develop an MRI-Inclusive Nomogram for Side-Specific Prediction of Extraprostatic Extension of Prostate Cancer
Background: To develop an international, multi-site nomogram for side-specific prediction of extraprostatic extension (EPE) of prostate cancer based on clinical, biopsy, and magnetic resonance imaging- (MRI) derived data. Methods: Ten institutions from the USA and Europe contributed clinical and side-specific biopsy and MRI variables of consecutive patients who underwent prostatectomy. A logistic regression model was used to develop a nomogram for predicting side-specific EPE on prostatectomy specimens. The performance of the statistical model was evaluated by bootstrap resampling and cross validation and compared with the performance of benchmark models that do not incorporate MRI findings. Results: Data from 840 patients were analyzed; pathologic EPE was found in 320/840 (31.8%). The nomogram model included patient age, prostate-specific antigen density, side-specific biopsy data (i.e., Gleason grade group, percent positive cores, tumor extent), and side-specific MRI features (i.e., presence of a PI-RADSv2 4 or 5 lesion, level of suspicion for EPE, length of capsular contact). The area under the receiver operating characteristic curve of the new, MRI-inclusive model (0.828, 95% confidence limits: 0.805, 0.852) was significantly higher than that of any of the benchmark models (p < 0.001 for all). Conclusions: In an international, multi-site study, we developed an MRI-inclusive nomogram for the side-specific prediction of EPE of prostate cancer that demonstrated significantly greater accuracy than clinical benchmark models.
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e863-e864
Added value of pre-biopsy prostate multiparametric MRI in biopsy-naïve patients: Preliminary results of the MRI-FIRST trial
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e863-e864
Added value of pre-biopsy prostate multiparametric MRI in biopsy-naïve patients: Preliminary results of the MRI-FIRST trial
- 20 January 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (2) , 46-47
Robot-assisted partial prostatectomy for anterior cancer
- 20 January 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (2) , 46-47
Robot-assisted partial prostatectomy for anterior cancer
- 1 April 2015
- Published by Elsevier in Progrès en Urologie
- Vol. 25 (5) , 274-281
Nodules testiculaires de l’homme infertile et échographie de contraste : étude préliminaire
- 1 April 2015
- Published by Elsevier in Progrès en Urologie
- Vol. 25 (5) , 274-281
Nodules testiculaires de l’homme infertile et échographie de contraste : étude préliminaire
- Open Access
- 1 December 2014
- Published by Hindawi Limited in BioMed Research International
- Vol. 2014, 1-11
Multiparametric MRI-Targeted TRUS Prostate Biopsies Using Visual Registration
Prebiopsy multiparametric prostate MRI (mp-MRI), followed by transrectal ultrasound-guided (TRUS-G) target biopsies (TB) of the prostate is a key combination for the diagnosis of clinically significant prostate cancers (CSPCa), to avoid prostate cancer (PCa) overtreatment. Several techniques are available for guiding TB to the suspicious mp-MRI targets, but the simplest, cheapest, and easiest to learn is “cognitive,” with visual registration of MRI and TRUS data. This review details the successive steps of the method (target detection, mp-MRI reporting, intermodality fusion, TRUS guidance to target, sampling simulation, sampling, TRUS session reporting, and quality insurance), how to optimize each, and the global indications of mp-MRI-targeted biopsies. We discuss the diagnostic yield of visually-registered TB in comparison with conventional biopsy, and TB performed using other registration methods.
- 1 December 2014
- Published by Hindawi Limited in BioMed Research International
- Vol. 2014, 1-11
Open AccessMultiparametric MRI-Targeted TRUS Prostate Biopsies Using Visual Registration
Prebiopsy multiparametric prostate MRI (mp-MRI), followed by transrectal ultrasound-guided (TRUS-G) target biopsies (TB) of the prostate is a key combination for the diagnosis of clinically significant prostate cancers (CSPCa), to avoid prostate cancer (PCa) overtreatment. Several techniques are available for guiding TB to the suspicious mp-MRI targets, but the simplest, cheapest, and easiest to learn is “cognitive,” with visual registration of MRI and TRUS data. This review details the successive steps of the method (target detection, mp-MRI reporting, intermodality fusion, TRUS guidance to target, sampling simulation, sampling, TRUS session reporting, and quality insurance), how to optimize each, and the global indications of mp-MRI-targeted biopsies. We discuss the diagnostic yield of visually-registered TB in comparison with conventional biopsy, and TB performed using other registration methods.
- 1 November 2014
- Published by Elsevier in Progrès en Urologie
- Vol. 24 (15) , 987-999
Imagerie des tumeurs des voies excrétrices supérieures : état de l’art pour le rapport scientifique annuel de l’Association française d’urologie
- 1 November 2014
- Published by Elsevier in Progrès en Urologie
- Vol. 24 (15) , 987-999
Imagerie des tumeurs des voies excrétrices supérieures : état de l’art pour le rapport scientifique annuel de l’Association française d’urologie